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Abstract: Boron oxide (B2O3) is derived from dehydration of boric acid and is a colorless, semitransparent, crystalline compound that
is moderately soluble in water. On the other hand, boron oxide is chemically hygroscopic. This gives the molecule the ability to soak
up water and adhere to tissues. Boron oxide can be used locally after tumor debulking in inoperable tumors and especially when the
tumor-free margin distance cannot be provided. For all these reasons we aimed to evaluate the in vitro test results of B2O3 in terms
of cytotoxicity, genotoxicity, apoptosis, and necrotic effects on L929 fibroblast cells and DLD-1 colorectal adenocarcinoma cells. Our
studies demonstrated that boron oxide compounds appear to be highly cytotoxic for both cell lines according to WST cell viability assay
(44.22% and 18.36% on DLD-1 and L929, respectively). Although no genotoxic effects were observed, boron oxide compounds showed
antiproliferative effects for both cell lines. The prepared boron oxide compounds may hold the potential to be applied locally to the
remaining tissue after surgery and further research and evaluation will be needed to determine its effectiveness.
Key words: Boron oxide, L929 fibroblast cells, DLD-1 colorectal adenocarcinoma cells, in vitro

1. Introduction
It is evident that cancer is a fatal public health problem
worldwide, and colorectal cancers among all cancers are
observed with a high frequency in both sexes. According to
the 2018 data of the American Cancer Research Institute,
colorectal cancer is the third most frequent cancer in
males and second most frequent in females. In addition,
in 2018, more than 1.8 million new cases were diagnosed
globally (AICR, 2018).
Prognosis is still limited in patients with metastatic
colorectal cancer, despite the emergence of targeted
therapy (e.g., cetuximab and bevacizumab) and
improvement of other treatment modalities (Nelson and
Thorson, 2009). Therefore, it appears that the development
of new chemoprophylactic agents is needed for the
prevention of colorectal cancer in early stages. Colorectal
cancer treatments are still obstructed by delayed diagnosis,
metastatic spread through portal blood or lymphatic
invasions, iatrogenic recurrence after surgical removal, and
failure of specificity in chemo- and radiotherapy (Midgley
and Kerr, 1999; Sugarbaker, 1999). Although systemic
chemotherapy is possibly the only choice for adjuvant

therapy to prevent metastatic spread after resection, local
recurrence (e.g., anastomotic leaks) may benefit from
local approaches (Sugarbaker, 1999). Compared to other
anticancer agents, the use and study of boron as a main
agent in colorectal cancers is rare in the literature. Although
the methods of administration and the areas of the tumor
for which they are applied are different and limited, the
research and treatment methods that have boron as a
common feature are as follows: boron neutron capture
therapy (BNCT) (Wada et al., 2018) uses it for the brain
tumor known as glioblastoma multiforme. On the other
hand, the hematological anticancer chemotherapeutic
agent called bortezomib is authorized for the therapy of
cases of multiple myeloma and a hematological anticancer
chemotherapeutic agent endorsed for the therapy of cases
of mantle cell lymphoma (Chattopadhyay et al., 2015).
When we look at the mechanisms of these treatments,
the main characteristic of BNCT can be summarized as
follows: targeting the destruction of a population of cells
identified as cancer cells and minimizing damage to
healthy cells. If we look at the physical principles of BNCT,
it appears to involve a dual component system [helium-4
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(4He) (i.e. α particle) and lithium-7 (7Li) nuclei] on
the basis of a nuclear reaction. Low-energy or thermal
neutrons are irradiated to the stable boron isotope (10B),
and 4He and 7Li are generated. These high-energy charged
particles lack the ability to move far. With this treatment,
which focuses directly on the tumor cell, the energy
is released into the tumor cell, thus directly damaging
the DNA and preventing the cells from reproducing
(Kahraman, 2004; Yakıncı and Kök, 2016). Since cancer
cells in brain tumors are selected and the damage to
normal body cells is at a minimal level, this method has
become a foremost treatment method (Kahraman, 2004;
Yakıncı and Kök, 2016). As mentioned above, bortezomib
is used as a chemotherapeutic agent for some hematologic
malignancies today; it is a modified dipeptidyl boronic acid
analog with antineoplastic activity that acts as a reversible
proteasome inhibitor (Chattopadhyay et al., 2015).
Another important point that drew our attention
while performing this study is that the boronic acid group
found in bortezomib is metabolized to the boric acid in
the body, and perhaps more importantly, its excretion
from the body and the metabolic process were found to
be smooth (Pekol et al., 2005). On the other hand, when
we look at the structure of boron oxide, it has the formula
of diboron trioxide (B2O3), with alternative names such
as boric anhydride, boron trioxide, boric oxide, and boric
acid anhydride.
Boron oxide synthesis can now be done very widely in
the chemical industry, and its first production in Turkey
was announced in 1994 (Kocakuşak, 1994). In this method,
boron oxide is obtained by a three-stage dehydration
process with microwave energy. It has been reported that
the boron oxides produced are of purity that can be used in
many industries, especially chemistry. Boric acid is slowly
heated up to 100 °C, followed by a loss of one mole of water,
and then converts into metaboric acid (HBO2). It continues
to be heated and at 140 °C it loses another mole of water
and converts into pyro- or tetraboric acid (H2B4O7). Finally,
when the heating is intensified, it loses all its water at red
heat (300 °C) and converts into boron trioxide (B2O3), and
it is obtained with the same purity (Demir, 2007). Boron
oxide forms as colorless, semitransparent, glassy lumps or
hard, white, odorless crystals. It has moderate solubility in
water at room temperature. Its melting property increases
as it is heated (NIH, 2019). It was stated that the structures
of boronic acid and boron oxide are very similar and are
coordinated with trigonal oxygen, and these two molecules
have an indistinguishable spectrum (Gilbert et al., 2000).
Bortezomib, a dipeptidyl boronic acid analog, is
metabolized to boronic acid. Dipeptidyl boronic acids
also have selective and potent proteasome inhibitor
properties (Adams et al., 1998; Smoum et al., 2012; Glynn,
et al., 2015), as well as a mechanism of inhibition similar
to that of NF-κB, suggesting that boron oxide may also
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have these properties. As a result of a literature review, we
found that the different molecular compounds of boron
have been studied so far only in limited numbers. Since we
saw that boron is not used as an anticancer agent except
for some certain types of cancers at the present time,
in order to expand the range of use of boron-centered
chemotherapeutic agents in medical cancer treatments in
the literature, we evaluated the effects of B2O3 (diboron
trioxide; boric acid anhydride) molecules as an in vitro
chemotherapeutic agent in terms of toxicity, genotoxicity,
and apoptotic and necrotic effects on colorectal tumor
cells.
Our study is original in regards to our experience and
results on the effect of B2O3 on colorectal cancer cells, since
there is a limited level of knowledge due to the limited
application of this compound in solid tumors to date.
2. Materials and methods
2.1. Study design
With this study, we aimed to determine the effect of
boron oxide molecules on colorectal cells. The contents
of 4 separate samples containing equal amounts of boron
oxide (B2O3) were as follows: the first group contained
boron oxide (B2O3), which is easily supplied in the
chemical industry; the second group included boron
oxide produced in laboratory conditions and boric acid,
which can be easily obtained from the chemical industry;
the third group included boron oxide that we produced
in laboratory conditions; and the fourth group contained
boron oxide and boric acid, both obtained from the
chemical industry. Each of these 4 separate samples were
divided into subgroups containing 20 µg/mL, 10 µg/mL, 5
µg/mL, and 2.5 µg/mL of the molecule, respectively.
Group I: Sample contained B2O3 obtained from the
chemical industry.
Group II: Sample contained B2O3 produced in the
laboratory + boric acid obtained from the chemical
industry.
Group III: Sample contained B2O3 produced in the
laboratory.
Group IV: Sample contained boric acid and B2O3
obtained from the chemical industry.
(The amount of boric acid in Group II and Group IV is
equal in both samples.)
B2O3 synthesis was done by dehydrating boric acid in
3 steps in a dry oven under laboratory conditions (at 100
°C, 140 °C, and 300 °C, respectively). As is clearly stated in
the literature, metaboric acid (HBO2) is formed after the
first stage, when the temperature reaches 140 °C; then one
mole of water is lost and the molecule is transformed into
pyro- or tetraboric acid (H2B4O7), and finally, in the final
heating phase (300 °C), by completely losing water, boron
trioxide (B2O3) is formed (Demir, 2007; Taşgın, 2018).
For calculation of dehydration, molar loss is calculated by
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following the weight change of the water with losses as a
result of each heating process.
Boron oxide was produced in the laboratory,
commercially obtained, or freshly prepared as dilutions
with deionized water and applied in the first 24 h; thus,
no stock or stabilization problems were experienced.
However, B2O3 is hygroscopic at room temperature and
moderately soluble in water (Ediz and Özdağ, 2001). As
with bortezomib, propylene glycol was chosen as a solvent
system for boron oxide due to its ease of liquid stabilization.
2.2. Cell cultures for fibroblast and colon cancer cells
Normal L929 (derivative of strain L mice fibroblast
cells) and DLD-1 (ATCC CCL-221) human colorectal
adenocarcinoma cells and also CHO (Chinese hamster
ovary) cells as a standard cell line for genotoxicity were
placed in flasks containing DMEM (Dulbecco’s modified
Eagle’s medium for L929 and CHO cell lines) and RPMI
1640 (Roswell Park Memorial Institute 1640 medium
developed from monolayer human leukemic cells in
suspension for DLD-1 cell line) with L-glutamine, 10%
fetal bovine serum FBS), and 1% antibiotics and remained
in a CO2 incubator conditioned with 5% CO2 at 37 °C for
48 h. For procuring cells, the cell culture medium was
removed and the cells were treated with trypsin-EDTA
(0.05%), and then cells were transferred to 15-mL Falcon
tubes and centrifuged at 2500 rpm for 2 min.
Removing the supernatant, the cells were counted and
required amounts of cells were used in the prospective
studies.
2.3. Cell viability with WST assay
L929 and DLD-1 cells were placed in 96-well plates (5 × 103
cells/well) containing DMEM and RPMI 1640, respectively,
with L-glutamine, 10% FBS, and 1% antibiotics. After the
plates were kept in a CO2 incubator (37 °C in 5% CO2) for
24 h until the cells were attached to the bottom of the plate,
the culture medium was replaced with fresh medium and
then the cells were treated with different concentrations
(20–2.5 µg/mL) of samples (Groups I–IV), and the
cytotoxicity on L929 and DLD-1 cells was evaluated by
WST1 colorimetric assay. After finishing the experiment,
the plates were instantly scanned in an ELISA Microplate
Reader (BioTek, USA) at 440-nm wavelength and the
percentage of cell viability for each group was assessed
with the definition of the control cell viability as 100%.
The variables are expressed as mean ± standard error
as calculated from 3 separate experiments. Significant
differences in the mean values were evaluated by t-test, and
values of P < 0.01 and P < 0.05 were considered statistically
significant.
2.4. Analysis of apoptotic and necrotic cells (live/dead
double staining)
Double staining (DS) of Hoechst dye with propidium
iodide (PI) is one of the methods that provide the

characterization and assessment of apoptosis and necrosis
in culture with the principle of scoring cell nuclei.
L929 and DLD-1 cells were cultured in 96-well plates
(5 × 103 cells/well) in DMEM and RPMI 1640 separately, in
complementary material with 10% FBS and 1% antibiotics
at 37 °C and 5% CO2 moist atmosphere conditions
overnight.
Cells were then treated with different concentrations
(20–2.5 µg/mL) of samples (Groups I–IV) for 24 h. When
the incubation was completed, the cell culture media were
separated from all wells and 70 µL of the DS solution,
containing 10 mL of PBS, 500 µL of Hoechst 33342 (200
µg/mL), 100 µL of PI (100 µg/mL), and 100 µL of RNAse
A (10 mg/mL), was added to the cells. The plate was then
coated with aluminum foil and incubated for 15 min in
an incubator. Both apoptotic and necrotic cells were
counted with an inverted fluorescence microscope (Leica
DM IL, Germany), via DAPI [apoptotic cells were stained
with Hoechst (green)] and FITC [necrotic cells were
stained with PI (red)] filters, respectively. The final data
were presented as percentages of green and red cells after
counting 100 cells from each sample over three randomly
selected areas.
Variables are stated as mean ± standard error as
calculated from 3 separate experiments.
The differences between the mean values of the
measurement results were calculated by t-test and P-values
are based on P < 0.05.
2.5. Micronucleus (MN) assay for genotoxicity
An in vitro MN assay was performed to determine the
frequency of MN in the cytoplasm of interphase cells. The
presence of MN in the cell is an indicator of chromosomal
damage. In this part of the study, to verify the potential
genotoxic effects of samples, CHO cells (Chinese hamster
ovary is a standardized cell line for genotoxicity assays)
were seeded in 12-well plates (104 cells/well) in 1 mL of
DMEM medium supplemented with 10% FBS and 1%
antibiotics.
The plates were then preserved in a CO2 incubator for
24 h. When the cells were inoculated to the base of the
plate, the cell culture medium was substituted with fresh
medium and a 10 µg/mL concentration of all samples (in
the final density) was placed into the wells. A final density
of 200 µg/mL ethyl methane sulfonate (EMS) was used
as a positive control. Following 44 h of culture (the time
required for 1.5-fold cell cycle time according to the OECD
Test Guideline 487), cytokinesis blockage was applied by
including 3 µg/mL of cytochalasin-B.
When the 72-h incubation period was complete,
ice-cold KCl (0.075 M) treatment for 2 min at room
temperature was followed by adding a few drops of 4%
formaldehyde to preserve the cytoplasm and fixation
with methanol-glacial acetic acid solution (Meth-Ac, 3:1
mixture). Wells were incubated in each solution for per 3
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min. Fixation was followed by painting with PI for MN.
After painting for 5 min, binucleated cells were observed
for each sample with a fluorescence microscope for MN,
nucleoplasmic bridges, and nuclear buds.
2.6. Cell proliferation assay using the xCELLigence
system
The xCELLigence system is a microelectronic biosensor
system for cell-based assays providing dynamic, realtime, label-free evaluation of proliferation, viability, and
cytotoxicity of cells (Urcan et al., 2010). This technology
was used to determine the proliferation of L929 and
DLD-1 cells according to the guidance of the instructions
of the provider (Roche Applied Science, Switzerland).
The xCELLigence RTCA analyzer measures resistance
variations in cell culture media found in E-plate wells
(with gold microelectrodes integrated into the bottom of
the wells) in the incubator and determines cell viability
and motility against toxic potency. The more cells that
accumulate on the electrodes, the bigger the increase in
electrode resistance.
However, cell number is not a factor determining the
impedance. Other factors like cell interaction strength with
the electrodes and cell morphology affect the impedance
measurement. Therefore, electrode resistance, which is
exhibited and recorded as cell index (CI) values, reflect
the degree of the biological status of monitored cells,
including the cell number, cell viability, and morphologic
and adhesiveness ability (Ramis et al., 2013). In this work,
for background reading, 100 µL of DMEM or RPMI 1640
was added to a 96-well E-plate and the plate was placed
into the xCELLigence incubation system for 10 min for
stabilization of the temperature of the plate and the device.
Followed by a background reading for 1 min, the E-plate
was taken out of the system and L929 and DLD-1 cells (5 ×
103 cells/well) were inoculated in the plate. The E-plate was
placed one more time for incubation and the system ran for
10 min to confirm whether the wells were read or not. For
cell joining and growth, the plate was read for 24 h. When
24 h was completed and the cells had reached the growth
phase, the E-plate was removed from the incubator and
the medium was discarded. Then a ﬁnal volume of 200 µL
of medium containing various concentrations of samples
from Groups I–IV (final concentrations of samples were
10 µg/mL and 5 µg/mL) was added to cells. Afterwards,
the plate was left for incubation for approximately 72 h to
observe the cell index and growth status of the cells.
2.7. Hematoxylin and eosin (H&E) staining
L929 and DLD-1 cells (104 cells/well) were incubated in
48-well plates containing DMEM and RPMI 1640. After
incubation with 20 µg/mL and 5 µg/mL concentrations of
the samples (Groups I–IV) for 24 h, the cells dyed with
H&E were examined with a light microscope for cellular
and nuclear morphologies (Leica, DMI 6000, Germany).
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Cell membrane integrity was impaired when
the specimens were applied to the cells at 20 µg/mL
concentration, so the images obtained in the case of
application of 5 µg/mL concentrations of the specimens
are shared in Section 3.
3. Results
3.1. WST assay for cytotoxicity
With this research, the cytotoxicities of the all groups’
samples (Groups I–IV) were tested against L929 and
DLD-1 cells. The 20, 10, 5, and 2.5 µg/mL concentrations
of all group samples were incubated with separate
cell lines for 24 h in cell culture medium as described
above. Additionally, wells containing only cells specified
as controls were also tested in cell culture medium.
Subsequently, the wells were read at 440 nm with an ELISA
plate reader. The percentage of viable cells was estimated at
various concentrations (20, 10, 5, and 2.5 µg/mL) against
% cell viability (shown in Figures 1A and 1B). In terms
of WST results, the concentrations of specimens did not
have a notable effect on cell mortality, except the 20 µg/mL
concentration of samples in both cell lines. An increase
of the samples’ concentrations caused a slight decrease
of cell viability in comparison to control cells. When
both types of cells (DLD-1 and L929) were treated with
the highest concentration of Group III samples (20 µg/
mL), cell viability was found to be significantly lower (P
< 0.01) compared to the other groups. Similar results were
obtained with DLD-1 cells. Briefly, the lowest cell viability
at the highest concentration was detected with the Group
III sample (45.22%), which was statistically significant (P <
0.05) compared to the other groups. On the other hand, the
highest cell viability was seen at the lowest concentration
for the sample from Group I (115.75%) on DLD-1 cells.
The cell viability (%) established based on mean
absorbance values at 440 nm is presented. Data are
given as mean ± standard error as calculated from
separate experiments. Lowercase letters mark statistically
significant differences.
3.2. Analysis of apoptotic and necrotic cells (live/dead
double staining)
To research the apoptotic and necrotic effects and the
relationship with the morphological changes for all samples
on L929 and DLD-1 cells, Hoechst 33342 fluorescent stain
was used in this study.
Respectively, all samples’ dilutions were arranged
at concentrations between 20 and 2.5 µg/mL with fresh
medium and applied to the cultivated normal and cancer
cell cultures. The interaction was followed continuously
for each group’s samples with cells for 24 h. In the doublestaining method, both apoptotic and necrotic cells images
are given (Figures 2A–2F and 3A–3F).
The Hoechst 33342 fluorescent stain is used to fix
DNA and obtain a dark blue color for cell nuclei when
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Figure 1. The cytotoxic effects of differing concentrations of specimens on L929 (A) and DLD-1 cells (B) as clarified by
WST assay.

observed by the DAPI filter with a fluorescent microscope.
The control group included only medium. There was no
apoptosis as there was no morphological difference in the
cell nuclei of the control group (Figures 2A and 3A).
No significant apoptotic effect was detected in the
Group I samples (Figure 2B and 3B).
Apoptotic cell nuclei broke apart and had shapeless
borders and brighter images compared to the nonapoptotic
cells (apoptotic cells are shown with arrows in Figures 2C
and 3C).
When we looked at the control group, we did not see
any morphological variations in the cell nuclei (Figures
2A and 2D). In some of the treated samples (samples of
Group I, Figure 2B, and samples of Group III, Figure 2C),
the apoptotic cell nuclei were stained with a stronger blue
(white arrows) (fluorescence compared to nonapoptotic
cells) (Figure 2C). A necrotic cell appearance was obtained
from the double-stain method via PI fluorescent stain. PI,

a fluorescent molecule, was chosen in the double-staining
procedure to define necrotic cancer cells. Although this
dye passes through the dead cell membranes and causes
cell nuclei staining in red, it does not pass through the
living cells’ membranes under fluorescent light with the
FITC filter. The L929 and DLD-1 cells were dyed with PI
fluorescent dye in double-staining solution. Necrotic cell
images are given in Figures 2D, 2F, 3D, and 3F. Normal
cell nuclei were found as green when investigated by
FITC fluorescent filter, but the images of the control
group showed no morphological differences in cell nuclei
(Figures 2D and 3D). The nuclei of necrotic cells were
determined to be red in color in wells treated with all
samples, especially at high concentrations (20 and 10 µg/
mL), by the utilized fluorescent microscope (Figures 2E,
2F, 3E, and 3F).
In the control group, no morphological differences
were seen in the cell nuclei (Figures 3A–3D). In some
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Figure 2. Apoptotic and necrotic L929 fibroblast cell images procured from the double-staining procedure.
A) Control group (Hoechst 33342); B) Group I sample (Hoechst 33342); C) Group III sample (Hoechst
33342); D) control group (PI); E) Group II sample (PI); F) Group IV sample (PI). Cells were treated with
10 µg/mL concentrations of samples. Determination of the scale was done according to a distance of 100
µm (200× magnification).

treated samples (Group II sample, Figure 3B, and Group IV
sample, Figure 3C), at the final concentration (10 µg/mL),
the apoptotic cell nuclei were stained with a stronger blue
(white arrows) (fluorescence compared to nonapoptotic
cells) (Figure 3C). Necrotic cell images were obtained via
the double-staining method using PI fluorescent stain.
An apoptotic effect was clearly observed for the 20 µg/
mL concentration of Group I and Group III samples for
L929 cells and all group samples for DLD-1 treated with
the same concentrations, given as % apoptotic indexes
in Figures 4 and 5. The apoptosis of the cells treated with
the Group I sample (20 µg/mL) was significantly less (P <
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0.05, indicated as “a”) than the necrosis for the same group
and concentration. In all other groups, apoptotic effects of
different concentrations were also found to be significantly
different than necrotic effects [P < 0.05; 20, 10, and 5 µg/
mL concentrations of Group II (indicated as “b”), 20 and
10 µg/mL concentrations of Group III (indicated as “c”),
20 and 5 µg/mL concentrations of Group IV (indicated
as “d”)]. As a consequence, the increase in concentration
caused a general enhancement of apoptosis.
The lowest necrotic effect was observed at the
concentration of 2.5 µg/mL for Group I and Group III
samples, and high necrotic effects were observed especially
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Figure 3. The double-staining procedure was used for obtaining apoptotic and necrotic DLD-1 colon
cancer cell images. A) Control group (Hoechst 33342); B) Group II sample (Hoechst 33342); C) Group IV
sample (Hoechst 33342); D) control group (PI); E) Group I sample (PI); F) Group III sample (PI). Cells
were treated with 10 µg/mL concentrations of the samples. The scale displays a distance of 100 µm (200×
magnification).

at the concentrations of 20 µg/mL and 10 µg/mL of samples
for L929 fibroblast cells and for 20 µg/mL concentrations
of Group I and Group IV samples for DLD-1 colon cancer
cells. Figures 4 and 5 show the apoptotic and necrotic cell
indexes of L929 and DLD-1 cells acquired from the double
staining of Hoechst and PI.
The findings showed that at the highest concentration
(20 µg/mL) of the group samples, except for the Group IV
sample, none of the samples caused a significant apoptotic
index, but necrotic indexes were >50 for all samples at the
highest concentration (20 µg/mL) for the L929 cell line.

3.3. Micronucleus assay for genotoxicity
In relation to the MN assay in CHO cells, no significant
increase in the frequency of micronucleated binucleated
cells was observed compared to the controls (Figure
6). Additionally, no further increase in micronucleus
induction was exhibited beyond the concentration of 10
µg/mL for all specimens.
3.4. Cell proliferation assay using xCELLigence system
Cell inhibition and antiproliferative effects of individual
samples of Groups I–IV on L929 and DLD-1 cells were
analyzed by WST1 and RTCA assays, respectively. Figures
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Figure 4. Apoptotic and necrotic indexes acquired for L-929 fibroblast cell cultures after incubation with different
concentrations of group samples. Data are specified as mean ± standard error as calculated from 3 different experiments.

Figure 5. The necrotic indexes obtained for L929 fibroblast cell and DLD-1 colon cancer cell cultures respectively after
incubation with various concentrations of extracts. Data are mean ± standard error as evaluated from 3 separate experiments.

1 and 7 exhibit the result of the tests obtained from
cytotoxicity and cell proliferation assays.
It can be seen in Figures 7A–7F that in cells treated
with samples of Groups I, II, III, and IV, proliferation was
reduced (>50%) in both cell cultures (L929 and DLD-1)
for both concentrations of 5 and 10 µg/mL, and there was
no observed proliferative effect.
3.5. Hematoxylin and eosin staining
In the last century, H&E stains have been commonly used
and they are still important for defining different tissue
types and morphologic changes. This histologic dye has
been successfully used for many years as it works efficiently
with various fixatives and plays a key role with its extensive
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range of cytoplasmic, nuclear, and extracellular matrix
features. With a poorly understood reaction, hematoxylin
has a dark blue-purple color and smudges nucleic acids.
On the other hand, eosin is pink and it dyes the proteins
nonspecifically. Interestingly, in specific tissue, nuclei are
stained blue, but the cytoplasm and extracellular matrix
have varying degrees of pink smudges (Fischer et al., 2008).
After staining with hematoxylin and eosin of L929
and DLD-1 cells, which were treated with 20 and 5 µg/mL
concentrations of samples, morphological variability could
be observed between the cells (5 µg/mL concentrations
of samples), as in Figure 8. This may be related to the
cytotoxic effects of the samples on the cells.

ALBUZ et al. / Turk J Biol

Figure 6. Micronucleated binucleated cell visualization status from micronucleus assay via PI fluorescent
stain. Fluorescence microscopy image of (A) CHO cells not processed with samples (nonpositive control
group). Cells were not micronucleated. (B) Cells reacted with EMS at a concentration of 200 µg/mL (positive
control); (C) cells exposed to the Group I sample at a concentration of 10 µg/mL; (D) Group II sample at a
concentration of 10 µg/mL, where white arrow shows micronucleus; (E) Group III sample at a concentration
of 10 µg/mL; (E) Group IV sample at a concentration of 10 µg/mL. Photographs were obtained by FITC filter
using a Leica inverted fluorescent microscope (400× magnification).

4. Discussion
Overall, there are three main methods for the treatment
of cancer. These methods are the administration of
chemotherapy, the administration of radiotherapy,

and surgery for resectable tumors. Surgery is naturally
more effective in early-stage tumors. However, cancer
cells can always remain as residue at the cellular level
(Nedunchezhian et al., 2016). At this stage, the efficacy
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Figure 7. Dynamic monitoring of L929 and DLD-1 cells treated with 5 and 10 µg/mL concentrations of samples using the real-time
analyzer (RTCA) SP. A) Group I sample (10 µg/mL); B) Group II sample (10 µg/mL); C) Group III sample (10 µg/mL); D) Group IV
sample (10 µg/mL); E) Group I sample (5 µg/mL); F) Group II sample (5 µg/mL); G) Group III sample (5 µg/mL); H) Group IV sample
(5 µg/mL). Red line: L929 cells treated with sample; blue line: L929 cells not treated with sample (control group); green line: DLD-1 cells
treated with sample; pink line: DLD-1 cells not treated with sample (control group).

and side effects of chemotherapy and radiotherapy gain
importance. To date, some studies have examined the
anticancer effects of boron in medicine and its effect
on general human health according to daily exposure.
Unfortunately, boron was not used in the medical field
until 2003 with the use of bortezomib (Velcade), an FDA-
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approved proteasome inhibitor, for various hematological
malignancies (Richardson, et al., 2003).
Following this, PT-100 (Val-boroPro, Talabostat),
which focus on dipeptidyl peptidases such as fibroblast
activation protein, has been started to be used in the field
of medicine in the framework of efforts to develop other
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Figure 8. Light microscopy micrographs of H&E-stained L929 and DLD-1 cells. (A)
L929 cells show morphological shapes such as relatively cylindrical (control group);
(B) DLD-1 cells are more round than L929 cells (control group); (C) L929 cells treated
with Group I sample (5 µg/mL); (D) DLD-1 cells treated with Group I sample (5 µg/
mL); (E) L929 cells treated with Group II sample (5 µg/mL); (F) DLD-1 cells treated
with Group II sample (5 µg/mL); (G) L929 cells treated with Group III sample (5 µg/
mL); (H) DLD-1 cells treated with Group III sample (5 µg/mL); (I) L929 cells treated
with Group IV sample (5 µg/mL); (J) DLD-1 cells treated with Group IV sample (5 µg/
mL). Images were taken under a Leica inverted light microscope (400× magnification).

boron-centered compounds. In 2004, a phase II clinical
trial of PT-100 was initiated in the treatment of advanced
non-small-cell lung cancer (Cunningham, 2007). The
compound, which was put on hold in 2007 due to efficacy

problems, has recently been considered as a therapeutic
drug for many metastatic cancers such as kidney cancer,
pancreatic adenocarcinoma, non-small-cell lung cancer,
and chronic lymphocytic leukemia, and phase II clinical
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studies are being carried out (Jansen et al., 2013). Okondo
et al. reported that Val-boroPro (PT-100, Talabostat)
induced strong antitumor immune responses in similar
cancer models (Okondo et al., 2018). In the same study,
they reported that Val-boroPro (PT-100, Talabostat) acts as
an immunostimulator in caspase-1-dependent cell death,
called pyroptosis (Okondo et al., 2018). Pyroptosis is one
of the forms of nonapoptotic cell death, but it is different
from necrosis (Tait et al., 2014). Namely, pyroptosis
acts on caspase 1-dependent cell death. Thus, a war is
started between host and pathogen mechanisms (cancer,
inflammatory diseases, microbial infections, etc.) for
pyroptosis and this is important in terms of cell viability.
Pathogen mechanisms aim to inhibit the pyroptosis
(Bergsbaken et al., 2009). Although the reasons and the
results are not fully understood, it has been pointed out
that IL-1b and IL-18 maturation may be associated with
caspase-1 and thus pyroptosis occurs for the release of
mature, inflammatory cytokines. It is also emphasized that
as a final response to the triggering of invasive factors that
defeat the host defense mechanism, it controls the spread
by killing the host cells. Sendler et al. also stated that
pyroptosis is a highly inflammatory type of cell death and
involves the activation of nuclear factor-kB. In addition,
they emphasized that it can be an alternative programmed
cell death pathway in cases where apoptosis does not work
(Sendler et al., 2016). Val-boroPro (PT-100, Talabostat)
activates this pathway. This subject, which requires further
research, has also attracted our attention and raises the
question of whether or not the necrotic cellular structure
that we have determined in our study is a mechanism of
pyroptosis for boron oxide.
Considering the mechanisms of action of bortezomib,
which we mentioned earlier, first we can say that it
reversibly inhibits the 26S proteasome, a large protease
complex (Geniş and Coşar, 2018). The inhibition of this
proteasome function has also come up as a strong strategy
for anticancer therapy. Bortezomib has been reported
to induce apoptosis in cancer cells as an inhibitor of
proteasome, and even green tea effectively antagonizes
its ability to induce apoptosis in cancer cells by the bonds
with the boronic acid portion of the bortezomib, with its
epigallocatechin-3-gallate structure (Glynn et al., 2015).
In fact, the tendency of bortezomib and boron
components to form covalent bonds allows the boron atom
to function as a strong Lewis acid (electron pair acceptor),
due to the presence of an empty p-orbital. As a result of
this, thanks to the empty p-orbital, which is open to a pair
of electrons, it can easily form covalent bonds with the
hydroxyl groups of biological nucleophiles such as serine
in the enzyme structures, carbohydrates, and nucleic acids
(Baker et al., 2009), and it was reported that this makes
it possible to create new compound structures that can
reduce necrosis. In contrast to the antagonistic effect of
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green tea for bortezomib, Curcuma longa has agonistic
effects with different borate-containing compounds. These
agonistic effects arise from some inhibitors enzymes such
as serine protease, aspartic protease, metalloprotease,
p-glutamyl transpeptidase, and threonine-based and
cysteine protease inhibitors (Smoum et al., 2012). On
the other hand, a transcription factor, NF-κB, can be
induced by controlling the signal activation steps. This
factor improves carcinogenesis and cancer progression by
controlling many genes involved in inhibition of apoptosis
in immuno-inflammatory responses. Colorectal cancer
metastases were found to be inhibited by inhibition of
NF-κB (Feng et al., 2016). Bortezomib is also capable of
specifically inhibiting nuclear factor NF-κB at this stage.
Bortezomib delays tumor growth in vivo and increases
the cytotoxic effects of radiation and chemotherapy,
as also shown by Engür and Dikmen (2017). Sun et al.
(2012) also showed that sodium butyrate suppresses colon
carcinogenesis by triggering colon cancer cell apoptosis,
dependent on the store-operated Ca2+ entry (SOCE). One
of the interesting points here is that although Sun et al.
claimed that the mechanism of this reaction is like a puzzle,
they indicated that 2-APB (2-aminoethoxydiphenyl
borate) contributes to the mechanism of action of sodium
butyrate with pharmacological blockade of SOCE (Sun et
al., 2012). The definitive role of diphenylboronic anhydride
(2APB) in the SOCE blockade was first demonstrated in
the literature by Dobrydneva and Blackmore (2001). As
we mentioned in Section 1, boron oxide is a dehydrated
state of boric acid, bortezomib is metabolized to boric
acid in the body at the same time, and the effect of boron
oxide with its hygroscopic properties is thought to be
higher on cells when applied. All these factors led us to
research boron oxide. In addition, when we look at the
daily boron levels for human beings, the tolerated upper
level limit defined by the US Institute of Medicine’s Food
and Nutrition Board is 20 mg/day for adults (Trumbo et
al., 2001).
The World Health Organization set the initial
recommended level of intake as 13 mg/day, but then they
increased this value and identified it as 0.4 mg/kg, or 28 mg/
day of boron for a human being at 70 kg (WHO, 1998). The
European Union has determined the maximum tolerable
level of intake as 10 mg/day based on body weight. The
acceptable daily intake for boron was determined as 0.16
mg of boron/kg per day by the 2013 EFSA Panel (EFSA,
2013). Therefore, boron safety limits are not within a
narrow spectrum like those of other chemotherapeutics.
The cytotoxic effect of the samples prepared at different
concentrations was investigated by WST test on both
L929 and DLD-1 cancer cell lines. We determined that
the cytotoxic activity was 55.78% for DLD-1 and 81.64%
for L929 when the highest concentration of the Group
III sample was used, indicating that cancer cells are more
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resistant than normal cells. Furthermore, we think that a
cytotoxic effect of 55.78% for DLD-1 is important.
Boron nitride nanotubes (BNNTs) are highly watersoluble nanostructured boron nitride compounds that
can be used in BNCT. Singh et al. (2016) examined the
cytotoxic effects of nanostructured boron nitride in HeLa
(cervical cancer) and human breast adenocarcinoma
(MCF-7) cells in their study, and after administration
of a 2 mg/mL dose of the drug in 24 h they found 60%
and 45% cytotoxicity, respectively. In normal cell culture
(HEK-293), they found this rate at the same dose and time
as 30% (Singh et al., 2016). The results of our cytotoxicity
tests are similar.
When cell death was investigated by dual staining test,
which is done through apoptotic or necrotic pathways,
compared with the control groups, the apoptotic cell index
was found to be higher for L929 (35%) than for DLD-1
(8.5%). Similar results were also obtained for necrotic cell
indices. The lower apoptosis in colon cancer cells (DLD-1)
than in human fibroblast cells (L929) is also due to the fact
that cancer cells with induced cytotoxic effects are more
aggressive and resistant.
Li et al. (2017) reported that empty boron nitride
(BN) nanospheres increased apoptosis in prostate cancer
as a result of controlled crystallization, and reduced cell
viability. When the results of this study by Li et al. were
evaluated, it was found that DU145 prostate cancer cells
had increased early and late apoptosis fractions of 16.96%–
32.68% and 14.42%–52.41%, respectively, after exposure
to BN spheres with different crystallinity properties (25
µg/mL) for three days (Li et al., 2017). Another similar
study was conducted by Rocca et al. (2016), and they
confirmed the potential toxicity of pectin-coated boron
nitride nanotubes (P-BNNTs) in terms of proliferation
of RAW 264.7 mouse macrophages, inductance of

oxidative stress, and apoptosis/necrosis phenomena in
the range of 0–50 µg/mL (Rocca et al., 2016). After 24
h of incubation with P-BNNTs, the measurements of
necrotic, early apoptotic, and late apoptotic cells ranged
between 4.4% and 11.5%, 0.3% and 2.2%, and 1.5% and
2.5%, respectively (Rocca et al., 2016).
In our study, in which we evaluated the effect of B2O3
on colorectal cancer cells, which we believe will contribute
to the literature, we have not observed any changes in
the morphological cells that we worked on. Additionally,
due to the detection of only one micronucleus formation
in the second sample, we see encouraging results for our
future studies. As a result, we think that stopping cell
proliferation in both the DLD-1 and L929 cell lines is a
favorable outcome that inhibits cancer development.
Boron oxide maybe applicable as a systemic, but it needs
to be researched with in vivo experimental next steps.
Although it has an undesirable necrotic effects on control
cell line L929, it can be utilized locally in intraoperative
cancer surgery because of its induced apoptosis and tumor
tissue destruction. In the present study, we identiﬁed
our boron oxide-based original molecule, which can be
effective on colon cancer, in terms of stimulating apoptosis
and necrosis without any genotoxic effects.
Boric acid anhydride (boron oxide) may play an
important role in terms of intraoperative application for
local use after tumor debulking for inoperable tumors or
especially when the tumor-free margin distance cannot be
provided. If this is confirmed by in vivo tests, it will be an
important step towards a novel drug. As a next step, we are
planning to build an animal model for colorectal cancer
with boron trioxide (B2O3). We believe that this boronbased compound should be focused on with its anticancer
effects, and multicenter national organization is crucial.
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